Treats megaloblastic anemias due to folic acid deficiency. ANDA 200753, held by Sagent Pharms. Leucovorin Calcium.
As of Nov 16, 2026, ANDA 200753 (Leucovorin Calcium Preservative Free), held by Sagent Pharms, was first approved by FDA on Sep 6, 2012, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Leucovorin rescue is indicated after high dose methotrexate therapy in osteosarcoma. Leucovorin Calcium for Injection is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. Leucovorin Calcium for Injection is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. Leucovorin Calcium for Injection is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 6, 2012 | Original application | Approved | None posted |
| Leucovorin Calcium Preservative FreeEQ 50MG BASE/VIAL · injectable;injection | Leucovorin Calcium | Rx |
| Leucovorin Calcium Preservative FreeEQ 100MG BASE/VIAL · injectable;injection | Leucovorin Calcium | Rx |
| Leucovorin Calcium Preservative FreeEQ 200MG BASE/VIAL · injectable;injection | Leucovorin Calcium | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters